I think so too.
What if their primary strategy (not saying right or wrong), was to go it alone, and it has just changed over the course of the past 60 days? Because raising funds has not panned out as previously projected.
So JH gets voted out of the board room, and gets a kick in the pants to get this product to market.
The Chinese part of the equation likes SPORT because they can't build anything like it, and really want to be in the medical/surgical segment. JH says, we need "$X" funding and the pps is too low at this time, because we don't want to create that much dilution. So we have to balance what we need and what you want. We can close the deal if you provide "$X," but we don't want "$X" to cost us another 100M shares. He offers a more of a performance based contract and the proposed timetable, which can close as soon as they come across with the funding. Not promises, actual transfer.
Also, say there were conversations since the unveiling of SPORT by other potential partners, but TITAN's plan all along was to go alone, or wait for the "can't pass this up" buyout. But now it's a new dynamic and they've come to the conclusion that they can't get to the promised land without a partner. So "other" conversations are taking place while the Chinese option is continually being developed.
I may not have all of the cards right, but I think those are the hands that are being played at the moment. My only question would be, "Who's talking with Titan?"
I have come to no conclusions other than these as possibilities, because of today's announcement with our potential Chinese partnership.
I still think SPORT is/has attracted potential suitors based on all of my previous points, from recent posts about the marketplace, competition, the need for growth by existing medical device companies, the real value of IP, and SPORT being a real product as of today.
JMO
Regards,
BK